In 12 Weeks, DD01 Matches 48-Week Survodutide Results, D&D Claims
[NA Eun-kyung, Edaily Reporter] SEOUL , June 16, 2025. D&D Pharmatech, a developer of glucagon-like peptide-1(GLP-1)-based therapies, announced that its investigational treatment for metabolic dysfunc신용카드 tion-associated steatohepatitis(MASH), DD01, achieved statistically significant results in its ongoi콜금리 ng Phase 2 trial in the Uni